In this way, risk-reducing surgery was raised as having been proven to reduce breast cancer risk in BRCA1/BRCA2 carriers, but also as something not usually considered when the focus is on ovarian cancer treatment. This evidence concerns the gene BRCA1 and ovarian carcinoma.